Paratek Phase IIb data shows omadacycline’s potential to address unmet needs in NTM treatment, says… GlobalData Nov 15, 2024 The placebo-controlled trial enrolled 66 patients with NTM pulmonary disease caused by MABc. In the study, oral omadacycline was…
